These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26181424)

  • 21. MEK inhibitor-induced dusky erythema: characteristic drug hypersensitivity manifestation in 3 patients.
    Patel U; Cornelius L; Anadkat MJ
    JAMA Dermatol; 2015 Jan; 151(1):78-81. PubMed ID: 25426865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dabrafenib in combination with trametinib for the treatment of metastatic melanoma.
    Awad MM; Sullivan RJ
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):25-33. PubMed ID: 25473943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trametinib for progressive pediatric low-grade gliomas.
    Kondyli M; Larouche V; Saint-Martin C; Ellezam B; Pouliot L; Sinnett D; Legault G; Crevier L; Weil A; Farmer JP; Jabado N; Perreault S
    J Neurooncol; 2018 Nov; 140(2):435-444. PubMed ID: 30097824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pneumocephalus in a Pediatric Patient with Glioma Receiving Trametinib.
    Gorsi H; Marupudi NI; Sood S; Altinok D; Yankelevich M
    Pediatr Neurosurg; 2020; 55(1):51-53. PubMed ID: 31661699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
    Queirolo P; Picasso V; Spagnolo F
    Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
    Schadendorf D; Amonkar MM; Stroyakovskiy D; Levchenko E; Gogas H; de Braud F; Grob JJ; Bondarenko I; Garbe C; Lebbe C; Larkin J; Chiarion-Sileni V; Millward M; Arance A; Mandalà M; Flaherty KT; Nathan P; Ribas A; Robert C; Casey M; DeMarini DJ; Irani JG; Aktan G; Long GV
    Eur J Cancer; 2015 May; 51(7):833-40. PubMed ID: 25794603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuropsychological impact of trametinib in pediatric low-grade glioma: A case series.
    Peterson RK; McKeown T; Tabori U; Bartels U; Bouffet E; Janzen L
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28690. PubMed ID: 32930446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cabozantinib for relapsed neuroblastoma: Single institution case series.
    Perisa MP; Storey M; Streby KA; Ranalli MA; Skeens M; Shah N
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28317. PubMed ID: 32343886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group.
    Stieglitz E; Lee AG; Angus SP; Davis C; Barkauskas DA; Hall D; Kogan SC; Meyer J; Rhodes SD; Tasian SK; Xuei X; Shannon K; Loh ML; Fox E; Weigel BJ
    Cancer Discov; 2024 Sep; 14(9):1590-1598. PubMed ID: 38867349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recalcitrant trametinib-induced paronychia treated successfully with topical timolol in a pediatric patient.
    Martínez-de-Espronceda I; Bernabeu-Wittel J; Azcona M; Monserrat MT
    Dermatol Ther; 2020 Jan; 33(1):e13164. PubMed ID: 31705590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospects for MEK inhibitors for treating cancer.
    Martin-Liberal J; Lagares-Tena L; Larkin J
    Expert Opin Drug Saf; 2014 Apr; 13(4):483-95. PubMed ID: 24597490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Too many targets, not enough patients: rethinking neuroblastoma clinical trials.
    Fletcher JI; Ziegler DS; Trahair TN; Marshall GM; Haber M; Norris MD
    Nat Rev Cancer; 2018 Jun; 18(6):389-400. PubMed ID: 29632319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
    Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Swann S; Legos JJ; Jin F; Mookerjee B; Flaherty K
    Lancet; 2015 Aug; 386(9992):444-51. PubMed ID: 26037941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.
    Uribe P; Anforth RM; Kefford RF; Fernandez-Peñas P
    Melanoma Res; 2014 Oct; 24(5):501-3. PubMed ID: 24922191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer.
    Cox DS; Papadopoulos K; Fang L; Bauman J; LoRusso P; Tolcher A; Patnaik A; Pendry C; Orford K; Ouellet D
    J Clin Pharmacol; 2013 Sep; 53(9):946-54. PubMed ID: 23893461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers.
    Ho MY; Morris MJ; Pirhalla JL; Bauman JW; Pendry CB; Orford KW; Morrison RA; Cox DS
    Xenobiotica; 2014 Apr; 44(4):352-68. PubMed ID: 23971497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trametinib.
    Zeiser R
    Recent Results Cancer Res; 2014; 201():241-8. PubMed ID: 24756797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiogenic Shock and Respiratory Failure in a Patient With Metastatic Melanoma Receiving Trametinib Therapy.
    Tseng D; Mason XL; Neilan TG; Sullivan RJ
    Oncologist; 2016 Sep; 21(9):1136-7. PubMed ID: 27388234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pediatric cancer genomics, a play rather than a portrait.
    Ramaswamy V; Taylor MD
    Nat Genet; 2015 Aug; 47(8):851-2. PubMed ID: 26220132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
    Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC
    J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.